Kesimpta (Ofatumumab) Pregnancy Registry

Inclusion Criteria:

Participants must meet all the criteria listed under the respective cohorts to enroll in that particular cohort of the registry:

Cohort 1: Kesimpta-Exposed Cohort

1. Pregnant women

2. Diagnosed with MS, with the indication validated by medical records when possible

3. Administered Kesimpta for the treatment of MS at any time from 166 days prior to thefirst day of the LMP, or up to and including the end of pregnancy

4. Agree to the conditions and requirements of the study including the interviewschedule, release of medical records, the dysmorphology examination of live borninfants (OTIS specific), and validated developmental performance questionnaire inlive born children

Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)

1. Pregnant women

2. Diagnosed with MS, with the indication validated by medical records when possible

3. May or may not have taken another medication for MS in the current pregnancy

4. Agree to the conditions and requirements of the study including the interviewschedule, release of medical records, the dysmorphology examination of live borninfants (OTIS specific), and validated developmental performance questionnaire inlive born children

Cohort 3: Healthy Comparison Cohort (Comparison Group 2):Kesimpta-OTIS sub-study specific

1. Pregnant women

2. Agree to the conditions and requirements of the study including the interviewschedule, release of medical records, the dysmorphology examination of live borninfants, and validated developmental performance questionnaire in live born children

Exclusion Criteria:

Women meeting any of the following criteria will be excluded from the cohort study:

Cohort 1: Kesimpta-Exposed Cohort

1. Women who have enrolled in the Kesimpta cohort study with a previous pregnancy

2. Women who have used Kesimpta for an indication other than a currently approvedindication

3. Women with exposure to any of the following medications within 5 half-lives (orpharmacodynamic effect when relevant) prior to conception:

• Other anti-CD20 monoclonal antibody: same class as Kesimpta

• S1P modulators: same class as Mayzent

• Cladribine (Mavenclad): Based on the US label, animal studies indicate thatthere is positive evidence of teratogenicity for Cladribine

• Teriflunomide (Aubagio): The teratogenecity of teriflunomide is unknown andcurrently under investigation.

• New medications (marketed after 2021) indicated for the treatment of MS will beevaluated for inclusion/exclusion criteria as the study progresses.

4. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancyhas ended prior to enrollment)

5. Results of diagnostic test(s) that are positive for a major structural defect priorto enrollment. However, women who have had any normal or abnormal prenatal screeningor diagnostic test prior to enrollment are eligible as long as the test result doesnot indicate a major structural defect.

Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)

1. Administered Kesimpta 166 days before the first day of LMP or anytime duringpregnancy

2. Women with exposure to any of the following medications within 5 half-lives (orpharmacodynamic effect when relevant) of conception:

• Anti CD-20 monoclonal antibody

• Cladribine (Mavenclad)

• S1P modulators

• Teriflunomide (Aubagio) New medications (marketed after 2021) indicated for thetreatment of MS will be evaluated for inclusion/exclusion criteria as the studyprogresses.

3. Women who have enrolled in the Kesimpta cohort or BAF312A2403 Mayzent cohort with aprevious pregnancy

4. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancyhas ended prior to enrollment)

5. Results of diagnostic test(s) that are positive for a major structural defect priorto enrollment. However, women who have had any normal or abnormal prenatal screeningor diagnostic test prior to enrollment are eligible as long as the test result doesnot indicate a major structural defect.

Cohort 3: Healthy Comparison Cohort (Comparison Group 2): Only applicable to Kesimpta-OTIS sub-study

1. Administered Kesimpta 166 days before or Mayzent 4 days after the first day of LMPor anytime during pregnancy

2. Women who have a diagnosis of a MS

3. Women who have a current diagnosis of any autoimmune disease

4. Women who have first contact with the project after prenatal diagnosis of any majorstructural defect

5. Women treated with Mayzent or Kesimpta for non-MS indication

6. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancyhas ended prior to enrollment)

7. Results of diagnostic test(s) that are positive for a major structural defect priorto enrollment. However, women who have had any normal or abnormal prenatal screeningor diagnostic test prior to enrollment are eligible as long as the test result doesnot indicate a major structural defect.

8. Women exposed to a known human teratogenic drugs during pregnancy